#USA #NIH Grant #Bozeman #pharmacogenomics #Golden Helix

Golden Helix Receives NIH SBIR Phase 2 Grant

Golden Helix, Inc., based in Bozeman, Montana, has recently announced the receipt of the NIH Small Business Innovation Research (SBIR) Phase 2 Grant, identified as 2R44HG013456-02. This grant, focusing on the development of a Pharmacogenomics Workflow, aims to identify biomarkers and tailor treatment options effectively for individual patients.

Pharmacogenomics is a rapidly advancing field that allows doctors to customize patient treatment plans based on their unique genetic makeup. By leveraging genetic information, healthcare providers can make informed decisions regarding drug selection, dosage, efficacy, and safety. The NIH SBIR grant will significantly bolster Golden Helix’s pharmacogenetic analytics, aligning them with next-generation sequencing (NGS) methodologies to enhance the precision and scalability of clinical healthcare solutions.

The Principal Investigator on this promising grant, Dr. Andreas Scherer—who also serves as the President and CEO of Golden Helix—expressed profound gratitude for the NIH’s ongoing support for their research endeavors. He stated, “We are extremely grateful for the long-standing support of the NIH for our research, spanning from CNV analysis to clinical interpretation, and now to pharmacogenomics. This latest grant is a testament to our commitment to bringing advanced research topics to the marketplace.”

In the ever-evolving landscape of healthcare, the demand for personalized treatment solutions is growing. Thanks to the financial support from NIH, Golden Helix is poised to enhance its precision medicine software. These advancements aim to equip healthcare professionals with tools that unearth actionable insights for individualized treatment plans based on a patient’s unique genetic profile.

Golden Helix has been recognized for delivering reliable bioinformatics solutions for over 25 years, with a client base encompassing hospitals, testing labs, research institutions, and national genome programs worldwide. Their powerful suite of tools for tertiary analysis and genomic warehousing empowers clients to identify disease-causing mutations, make personalized treatment decisions, and accelerate research breakthroughs particularly in oncology and rare diseases. The recent NIH funding adds to the $7 million the company has accumulated since 2017, which reflects their ongoing commitment to developing innovative solutions in the healthcare arena.

As the pharmaceutical industry increasingly turns towards precision medicine, the focus on pharmacogenomics is becoming essential. Golden Helix aims to lead the way in creating solutions that meet this growing need, making tailored medicine a reality for countless patients. With support from significant stakeholders within the NGS sector, this initiative highlights the importance placed on advancing this critical research, not just for Golden Helix but for the future of healthcare as a whole.

In summary, the NIH SBIR Phase 2 grant represents a crucial step forward for Golden Helix in their ongoing mission to enhance pharmacogenomic analytics. With the ultimate goal of advancing personalized medicine, the company continues to garner support from the NIH and the broader scientific community, positioning itself at the forefront of innovation in the field of healthcare.

For further inquiries, Hayley Karol, the Technical Marketing Specialist at Golden Helix, can be reached at (406) 414-9973 or via email at [email protected]